Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
Blood|November 23, 2016
How I treat FLT3-mutated AMLKeith W Pratz, Mark Levis
Expert Review of Hematology|November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitorAmir T Fathi, Mark Levis
British Journal of Haematology|October 15, 2013
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinaseXiaochuan Yang, Amy Sexauer, Mark Levis
British Journal of Haematology|July 28, 2006
Constitutively activated FLT3 phosphorylates BAD partially through pim-1Kyu-Tae Kim, Mark Levis, Donald Small
Blood|May 6, 2004
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsMark Levis, Rosalyn Pham, B Douglas Smith, et al.
Leukemia Research|March 19, 2026
A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapyAlexander Ambinder, Mark Levis, Xin Wang, et al.
Blood|September 18, 2004
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expressionPatrick Brown, Mark Levis, Sheila Shurtleff, et al.
The Journal of Biological Chemistry|December 3, 2004
FLT3/ITD mutation signaling includes suppression of SHP-1Peili Chen, Mark Levis, Patrick Brown, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 8, 2016
Systemic effects of low-dose dopamine during administration of cytarabineJames Connelly, Dina J Benani, Matthew Newman, et al.
Blood|October 19, 2006
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysObdulio Piloto, Melissa Wright, Patrick Brown, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Blood|November 23, 2016
How I treat FLT3-mutated AMLKeith W Pratz, Mark Levis
Expert Review of Hematology|November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitorAmir T Fathi, Mark Levis
British Journal of Haematology|October 15, 2013
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinaseXiaochuan Yang, Amy Sexauer, Mark Levis
British Journal of Haematology|July 28, 2006
Constitutively activated FLT3 phosphorylates BAD partially through pim-1Kyu-Tae Kim, Mark Levis, Donald Small
Blood|May 6, 2004
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsMark Levis, Rosalyn Pham, B Douglas Smith, et al.
Leukemia Research|March 19, 2026
A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapyAlexander Ambinder, Mark Levis, Xin Wang, et al.
Blood|September 18, 2004
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expressionPatrick Brown, Mark Levis, Sheila Shurtleff, et al.
The Journal of Biological Chemistry|December 3, 2004
FLT3/ITD mutation signaling includes suppression of SHP-1Peili Chen, Mark Levis, Patrick Brown, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 8, 2016
Systemic effects of low-dose dopamine during administration of cytarabineJames Connelly, Dina J Benani, Matthew Newman, et al.
Blood|October 19, 2006
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysObdulio Piloto, Melissa Wright, Patrick Brown, et al.
Pageof 10